Literature DB >> 7237465

Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.

C B Vaughn, F Panettiere, T Thigpen, R Bottomley, B Hoogstraten, B Samal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7237465

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  8 in total

1.  Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer.

Authors:  M Bontenbal; A S Planting; J Verweij; R de Wit; W H Kruit; G Stoter; J G Klijn
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

Review 2.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

3.  Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer.

Authors:  C Manegold; P Worst; J Bickel; H Schmid; P Drings; M Kaufmann
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 4.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  Phase II study with etoposide in previously untreated advanced breast cancer.

Authors:  H E Wander; W Rauschning; D Meyer; W Achterrath; G A Nagel
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association.

Authors:  G W Thomas; H B Muss; D V Jackson; J McCulloch; W Ramseur; J McFarland; H Hoen; M Pavy; R Heath
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Chronic oral etoposide in advanced breast cancer.

Authors:  H Palombo; J Estapé; N Viñolas; J J Grau; J M Mañé; M Daniels; B Mellado
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 8.  Chemotherapy of breast cancer.

Authors:  L S Perlow; J F Holland
Journal:  Med Oncol Tumor Pharmacother       Date:  1984
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.